3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Virus Diseases
2
Urinary Bladder Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Carcinoma
1
Brain Neoplasms
1
Adenoviridae Infections
1
Interventions
valrubicin
3
dodecyl maltoside
3
Mitomycin
3
Gemcitabine
3
durvalumab
2
Cystoscopy
2
toripalimab
1
pembrolizumab
1
enfortumab vedotin
1
cemiplimab
1
apaziquone
1
Tomography, X-Ray Computed
1
Surveys and Questionnaires
1
Standard of Care
1
Oncolytic Virotherapy
1
Nivolumab
1
Magnetic Resonance Imaging
1
Interferons
1
Imiquimod
1
Histamine Antagonists
1
Electrocardiography
1
Docetaxel
1
Diphenhydramine
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
BCG Vaccine
1
Acetaminophen
1
ALT-801
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma in Situ
×
Oncolytic Virotherapy
×
Genitourinary
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled